Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2020 - 12 - 07 save search
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
Published: 2020-12-07 (Crawled : 22:00) - globenewswire.com
AGIO | News | $29.52 0.31% 0.3% 750K
|
Health Technology
|
| O: -9.8%
H: 0.0%
C: -6.89%
disease phase 3 phase 1 phase 2
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Published: 2020-12-07 (Crawled : 14:00) - globenewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -1.99%
H: 1.94%
C: -2.54%
positive results trial phase 2 duchenne
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
Published: 2020-12-07 (Crawled : 13:05) - globenewswire.com
KROS | $58.345 -1.03% -1.04% 350K
|
Health Technology
|
| O: -0.36%
H: 2.91%
C: -2.8%
results trial phase 3 phase 1 phase 2 preclinical pre-clinical
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Published: 2020-12-07 (Crawled : 13:02) - globenewswire.com
ONCT | News | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: 48.5%
H: 23.29%
C: 0.76%
phase 3 phase 1 phase 2
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: 0.0%
H: 2.47%
C: -19.01%
phase 3 phase 1 phase 2 t-cell
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -2.91%
H: 0.0%
C: -7.0%
trial phase 3 phase 1 phase 2 clinical hold
ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
Published: 2020-12-07 (Crawled : 12:01) - globenewswire.com
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: -1.17%
H: 2.55%
C: -2.97%
cancer phase 2 agx148
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability
Published: 2020-12-07 (Crawled : 11:01) - globenewswire.com
HOOK | $0.7317 -4.34% -4.54% 420K
|
Health Technology
|
| O: 2.13%
H: 8.6%
C: 6.34%
cancer therapy treatment phase 3 phase 1 phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.